EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer

Andrea Gottardo, Tancredi Didier Bazan Russo, Alessandro Perez, Marco Bono, Emilia Di Giovanni, Enrico Di Marco, Rita Siino, Carla Ferrante Bannera, Clarissa Mujacic, Maria Concetta Vitale, Silvia Contino, Giuliana Iannì, Giulia Busuito, Federica Iacono, Lorena Incorvaia, Giuseppe Badalamenti, Antonio Galvano, Antonio Russo, Viviana Bazan, Valerio Gristina

Cytopathology · 2024-11 · 35 (6) · 664-670

DOI: 10.1111/cyt.13396 ↗
AbstractBibliografische Angaben

Abstract

Abstract The transformative role of artificial intelligence (AI) and multiomics could enhance the diagnostic and prognostic capabilities of liquid biopsy (LB) for lung cancer (LC). Despite advances, the transition from tissue biopsies to more sophisticated, non‐invasive methods like LB has been impeded by challenges such as the heterogeneity of biomarkers and the low concentration of tumour‐related analytes. The advent of multiomics – enabled by deep learning algorithms – offers a solution by allowing the simultaneous analysis of various analytes across multiple biological fluids, presenting a paradigm shift in cancer diagnostics. Through multi‐marker, multi‐analyte and multi‐source approaches, this review showcases how AI and multiomics are identifying clinically valuable biomarker combinations that correlate with patients' health statuses. However, the path towards clinical implementation is fraught with challenges, including study reproducibility and lack of methodological standardization, thus necessitating urgent solutions to solve these common issues.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →